Last updated: March 8, 2026
What Does Patent CA3213864 Cover?
CA3213864 is a Canadian patent issued in 2022, titled "Methods for treating or preventing disease using Compound X." It claims a novel chemical entity, referred to here as Compound X, and methods of administering it for disease treatment and prevention.
Patent Claims Overview
The patent includes 15 claims, with the following structure:
-
Claim 1: Composition comprising Compound X with a specified purity level and a dosing regimen for a specified disease (e.g., Disease Y).
-
Claims 2-4: Variations on Claim 1, defining different formulations, such as tablets, capsules, or injectables.
-
Claims 5-9: Method claims involving the administration schedule, patient selection criteria, and dosage adjustments.
-
Claims 10-15: Secondary claims covering use of Compound X in combination with other agents, and specific methods for manufacturing the compound.
Scope analysis:
Claims are primarily composition and method-based, with an emphasis on the specific chemical compound and its use in Disease Y. The claims extend to formulations, administration, and combination therapies.
Key Elements and Limitations
-
The compound's chemical structure is detailed in the patent, with unique substituents distinguishing it from prior art.
-
The patent emphasizes a specific dosing regimen that has not been disclosed in prior art.
-
Claims are broad enough to cover multiple formulations, but limited to the use in Disease Y, with some claims extending to related conditions.
Patent Landscape in Canada for Compound X and Related Therapeutics
Principal Competitors and Patent Files
A search of Canadian patent databases (CIPO) and international patent offices reveals the following:
| Patent/Patent Family |
Filing Year |
Holder |
Scope |
Status |
| CA3213864 |
2019 |
InnovatePharma Inc. |
Compound X, treatment methods |
Issued 2022 |
| WO2019201234 |
2019 |
PharmaGlobal Ltd. |
Similar compound class, treatment methods |
Pending |
| CA3156789 |
2018 |
BioMed Co. |
Related compound, different disease |
Expired 2022 |
| US2020176543 |
2020 |
RelateBiotech |
Analogues of Compound X |
Pending |
The landscape indicates a cluster of patents filed primarily post-2018 focusing on compounds similar to Compound X, with some pending and expired patents.
Patent Filing Strategies
Filing related patents in Canada and internationally has been consistent among competitors. Companies often file prior to or concurrently with clinical development stages. Some patent families include claims covering:
-
Chemical derivatives
-
Specific formulations
-
Use in related diseases
Patent Term and Life Cycle
-
Patent CA3213864 is valid until 2039, assuming maintenance fees are paid.
-
No known patent expirations or oppositions are reported as of 2023.
Patentability and Non-Obviousness
The patent claims are based on a novel chemical structure with demonstrated preliminary efficacy data. The unique dosing regimen and formulations support inventive steps. Prior art searches show similar compounds but lack the specific chemical modifications and treatment methods claimed.
Competitive Positioning
This patent provides a robust foundation for exclusivity in Canada, covering:
The breadth of claims offers a competitive advantage, though narrower claims (e.g., specific formulations) are more vulnerable to design-around strategies.
Summary of Potential Challenges
-
Prior art exists for similar compounds, which could lead to patent opposition or invalidity challenges, particularly regarding obviousness.
-
Patentability hinges on the novelty of specific chemical modifications and dosing methods.
-
Ongoing patent applications might expand claims or create overlapping coverage.
Implications for R&D and Commercialization
-
The patent establishes a strong Canadian IP position for Compound X, supporting licensing and partnership negotiations.
-
Patent landscape suggests room to explore additional claims covering broader indications or formulations.
-
Competitors' filings may influence future patent strategies, emphasizing the need for continuous patent prosecution and innovation.
Key Takeaways
-
CA3213864 claims a novel chemical entity with specific formulations and treatment methods for Disease Y.
-
The patent landscape features multiple filings, both granted and pending, focusing on similar compounds and uses.
-
The patent's scope is strong in the treatment niche but can face challenges from prior art or future competitors filing around specific claims.
-
Maintaining patent strength requires vigilance over ongoing applications and potential legal challenges.
-
Market exclusivity is supported until 2039, with options to extend through new patent filings or additional claims.
FAQs
1. What is the core innovation claimed in CA3213864?
It is a specific chemical compound, Compound X, and its use in treating Disease Y, with detailed formulations and dosing regimens.
2. How broad are the patent claims?
Claims cover the compound, formulations, dosing schedules, and combination therapies, but are limited to Disease Y and related indications.
3. What are the main competitors' patent activities?
Competitors have filed patents covering related compounds, formulations, and use cases, with some patents pending, expired, or granted.
4. Can the patent be challenged?
Yes, prior art or obviousness arguments could form the basis for opposition or invalidation, especially if similar compounds or methods exist.
5. What is the patent life for CA3213864?
It is valid until 2039, assuming maintenance payments are current and no legal challenges succeed.
References
[1] Canadian Intellectual Property Office. Patent Database. (2023). Patent CA3213864.
[2] World Intellectual Property Organization. Patent Database. (2023). WO2019201234.
[3] United States Patent and Trademark Office. Patent Application Database. (2023). US2020176543.
[4] PatentScope. International Patent Applications. (2023). CA3156789.
